Take a Closer Look at the Promise of Our iADC Next-Gen Technology
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Six Product Candidates Advancing in the Clinic and Late-Stage Discovery Programs
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.
Diversity, Equity, Inclusion and Belonging (DEIB)
Our Commitment to Change.
Sutro Biopharma has partnered with California Life Sciences Association (CLSA) to create a more diverse industry to spark solutions for a better healthier world. CLSA members have raised $1M with a goal of sustaining 3-year commitments of $1M annually for Racial & Social Equity Initiative We Commit To Change